Based on the BALAXI PHARMACEUTICALS LIMITED stock forecast from 0 analysts, the average analyst target price for BALAXI PHARMACEUTICALS LIMITED is not available over the next 12 months. BALAXI PHARMACEUTICALS LIMITED’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of BALAXI PHARMACEUTICALS LIMITED is Bullish , which is based on 6 positive signals and 2 negative signals. At the last closing, BALAXI PHARMACEUTICALS LIMITED’s stock price was INR 611.50. BALAXI PHARMACEUTICALS LIMITED’s stock price has changed by +6.98% over the past week, +12.62% over the past month and +14.75% over the last year.
No recent analyst target price found for BALAXI PHARMACEUTICALS LIMITED
No recent average analyst rating found for BALAXI PHARMACEUTICALS LIMITED
Frequently Asked Questions About BALAXI PHARMACEUTICALS LIMITED (BALAXI:NSE) Stock
Stock Target Advisor's fundamental analysis for BALAXI PHARMACEUTICALS LIMITED's stock is Bullish .
Unfortunately we do not have enough data on BALAXI:NSE's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on BALAXI:NSE's stock to indicate what its average analyst target is.
BALAXI:NSE stock's Price/Earning ratio is 9.23.
Our analysis grades BALAXI:NSE stock's Price / Earning ratio at A+. This means that BALAXI:NSE stock's Price/Earning ratio is above 0% of the stocks in the Other sector in the NSE exchange.
Based on this BALAXI:NSE may be undervalued for its sector.
The last closing price of BALAXI:NSE's stock was INR 611.50.
The most recent market capitalization for BALAXI:NSE is INR 6.23B.
Unfortunately we do not have enough analyst data on BALAXI:NSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains BALAXI PHARMACEUTICALS LIMITED's stock.
Sorry, we do not have any data on the number of employees for BALAXI PHARMACEUTICALS LIMITED.
Sorry we do not have any infomation available on BALAXI PHARMACEUTICALS LIMITED's address.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low debt
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BALAXI:NSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
